Home > En > R and D > Partnership > Research partnerships

Research partnerships

It is the policy of Arronax to propose and get involved in research partnerships. Purely academic or academia/industry partnerships are considered when their object is consistent with the original missions of Arronax.
Accordingly, Arronax is currently a partner of the Région Pays de la Loire NucSan (Nuclear Technologies for Health) research project, which, in addition to the Arronax GIP, includes 10 laboratories of Nantes and Angers, and of the “Investissements d’Avenir” laboratory of Excellence IRON (Innovative Radiopharmaceuticals for Oncology and Neurology), which brings together laboratories and clinical centers from Nantes, Angers, Tours, Caen, Toulouse, Orléans, Rennes and Strasbourg.
The ArronaxPlus equipment of excellence of the “Investissements d’Avenir” program another example of scientific and technological consortium, managed by Arronax with the goal of offering a coordinated group of technological platforms, from chemistry to clinical nuclear medicine, to help in the development of radiopharmaceuticals in all medical domains including oncology, cardiology and neurology.
Arronax is also a partner in two government subsidized academia/industry partnership: Theranean and QuantiCardi. These two projects are funded through the FUI (Fonds Unique Interministériel) managed by the Oséo agency:

  • Theranean (Therapy through Neutron Activation using Nanoparticles) aims at developing a neutron activation device driven by a highly intense 70 MeV proton beam delivered by the Arronax cyclotron to activate holmium nano and microparticles for the treatment of cancer by brachytherapy. It is coordinated by the AAA company (Saint-Génis-Pouilly, France) and involves Subatech, the Nano-H S.A.S. company, the University Claude Bernard Lyon 1, the INSA-MATEIS (CNRS) laboratory, in collaboration with the Hospices Civils de Lyon.
  • The objective of the QuantiCardi project is the preindustrial development of an integrated solution consisting in innovative components dedicated to the imaging of myocardic perfusion by Positron Emission Tomography (PET) to measure myocardic blood flow and the coronary reserve. A subnormal coronary reserve is symptomatic coronary insufficiency, disease responsible for 30 50% of death by cardiopathy in Europe. The project is headed by Lemer PAX company and involves Keosys, Subatech, IRCCyN-IVC and the CRCNA.

A large collaborative project, aiming at creating a national academic and industrial cluster in molecular radiotherapy, is being developed with Atlanpole Biotherapies in response to the “Projets Structurants des Pôles de Compétivité call for tender of the”Investissements d’Avenir".